288 related articles for article (PubMed ID: 33734864)
1. Low-Dose Tamoxifen for Mammographic Density Reduction: A Randomized Controlled Trial.
Eriksson M; Eklund M; Borgquist S; Hellgren R; Margolin S; Thoren L; Rosendahl A; Lång K; Tapia J; Bäcklund M; Discacciati A; Crippa A; Gabrielson M; Hammarström M; Wengström Y; Czene K; Hall P
J Clin Oncol; 2021 Jun; 39(17):1899-1908. PubMed ID: 33734864
[TBL] [Abstract][Full Text] [Related]
2. Randomized double-blind 2 x 2 trial of low-dose tamoxifen and fenretinide for breast cancer prevention in high-risk premenopausal women.
Decensi A; Robertson C; Guerrieri-Gonzaga A; Serrano D; Cazzaniga M; Mora S; Gulisano M; Johansson H; Galimberti V; Cassano E; Moroni SM; Formelli F; Lien EA; Pelosi G; Johnson KA; Bonanni B
J Clin Oncol; 2009 Aug; 27(23):3749-56. PubMed ID: 19597031
[TBL] [Abstract][Full Text] [Related]
3. Effects of tamoxifen on normal breast tissue histological composition: Results from a randomised six-arm placebo-controlled trial in healthy women.
Gabrielson M; Hammarström M; Bäcklund M; Bergqvist J; Lång K; Rosendahl AH; Borgquist S; Hellgren R; Czene K; Hall P
Int J Cancer; 2023 Jun; 152(11):2362-2372. PubMed ID: 36637153
[TBL] [Abstract][Full Text] [Related]
4. Mammographic density change in a cohort of premenopausal women receiving tamoxifen for breast cancer prevention over 5 years.
Brentnall AR; Warren R; Harkness EF; Astley SM; Wiseman J; Fox J; Fox L; Eriksson M; Hall P; Cuzick J; Evans DG; Howell A
Breast Cancer Res; 2020 Sep; 22(1):101. PubMed ID: 32993747
[TBL] [Abstract][Full Text] [Related]
5. Tamoxifen and breast density in women at increased risk of breast cancer.
Cuzick J; Warwick J; Pinney E; Warren RM; Duffy SW
J Natl Cancer Inst; 2004 Apr; 96(8):621-8. PubMed ID: 15100340
[TBL] [Abstract][Full Text] [Related]
6. Tamoxifen-induced reduction in mammographic density and breast cancer risk reduction: a nested case-control study.
Cuzick J; Warwick J; Pinney E; Duffy SW; Cawthorn S; Howell A; Forbes JF; Warren RM
J Natl Cancer Inst; 2011 May; 103(9):744-52. PubMed ID: 21483019
[TBL] [Abstract][Full Text] [Related]
7. RAZOR: A Phase II Open Randomized Trial of Screening Plus Goserelin and Raloxifene Versus Screening Alone in Premenopausal Women at Increased Risk of Breast Cancer.
Howell A; Ashcroft L; Fallowfield L; Eccles DM; Eeles RA; Ward A; Brentnall AR; Dowsett M; Cuzick JM; Greenhalgh R; Boggis C; Motion J; Sergeant JC; Adams J; Evans DG
Cancer Epidemiol Biomarkers Prev; 2018 Jan; 27(1):58-66. PubMed ID: 29097444
[No Abstract] [Full Text] [Related]
8. A Randomized Phase IIb Study of Low-dose Tamoxifen in Chest-irradiated Cancer Survivors at Risk for Breast Cancer.
Bhatia S; Palomares MR; Hageman L; Chen Y; Landier W; Smith K; Umphrey H; Reich CA; Zamora KW; Armenian SH; Bevers TB; Blaes A; Henderson T; Hodgson D; Hudson MM; Korde LA; Melin SA; Merajver SD; Overholser L; Pruthi S; Wong FL; Garber JE
Clin Cancer Res; 2021 Feb; 27(4):967-974. PubMed ID: 33272980
[TBL] [Abstract][Full Text] [Related]
9. Mammographic density changes following discontinuation of tamoxifen in premenopausal women with oestrogen receptor-positive breast cancer.
Kim WH; Cho N; Kim YS; Yi A
Eur Radiol; 2018 Aug; 28(8):3176-3184. PubMed ID: 29626240
[TBL] [Abstract][Full Text] [Related]
10. A Randomized Controlled Trial of Green Tea Extract Supplementation and Mammographic Density in Postmenopausal Women at Increased Risk of Breast Cancer.
Samavat H; Ursin G; Emory TH; Lee E; Wang R; Torkelson CJ; Dostal AM; Swenson K; Le CT; Yang CS; Yu MC; Yee D; Wu AH; Yuan JM; Kurzer MS
Cancer Prev Res (Phila); 2017 Dec; 10(12):710-718. PubMed ID: 28904061
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant tamoxifen-induced mammographic breast density reduction as a predictor for recurrence in estrogen receptor-positive premenopausal breast cancer patients.
Ko KL; Shin IS; You JY; Jung SY; Ro J; Lee ES
Breast Cancer Res Treat; 2013 Dec; 142(3):559-67. PubMed ID: 24233999
[TBL] [Abstract][Full Text] [Related]
12. Preliminary results on safety and activity of a randomized, double-blind, 2 x 2 trial of low-dose tamoxifen and fenretinide for breast cancer prevention in premenopausal women.
Guerrieri-Gonzaga A; Robertson C; Bonanni B; Serrano D; Cazzaniga M; Mora S; Gulisano M; Johansson H; Formelli F; Intra M; Latronico A; Franchi D; Pelosi G; Johnson K; Decensi A
J Clin Oncol; 2006 Jan; 24(1):129-35. PubMed ID: 16382122
[TBL] [Abstract][Full Text] [Related]
13. A randomized, placebo-controlled trial (NCIC CTG MAP1) examining the effects of letrozole on mammographic breast density and other end organs in postmenopausal women.
Cigler T; Tu D; Yaffe MJ; Findlay B; Verma S; Johnston D; Richardson H; Hu H; Qi S; Goss PE
Breast Cancer Res Treat; 2010 Apr; 120(2):427-35. PubMed ID: 19967558
[TBL] [Abstract][Full Text] [Related]
14. Side effects of low-dose tamoxifen: results from a six-armed randomised controlled trial in healthy women.
Hammarström M; Gabrielson M; Crippa A; Discacciati A; Eklund M; Lundholm C; Bäcklund M; Wengström Y; Borgquist S; Bergqvist J; Eriksson M; Tapia J; Czene K; Hall P
Br J Cancer; 2023 Jul; 129(1):61-71. PubMed ID: 37149701
[TBL] [Abstract][Full Text] [Related]
15. Mammographic density reduction is a prognostic marker of response to adjuvant tamoxifen therapy in postmenopausal patients with breast cancer.
Li J; Humphreys K; Eriksson L; Edgren G; Czene K; Hall P
J Clin Oncol; 2013 Jun; 31(18):2249-56. PubMed ID: 23610119
[TBL] [Abstract][Full Text] [Related]
16. Mammographic Density Reduction as a Prognostic Marker for Postmenopausal Breast Cancer: Results Using a Joint Longitudinal-Survival Modeling Approach.
Andersson TM; Crowther MJ; Czene K; Hall P; Humphreys K
Am J Epidemiol; 2017 Nov; 186(9):1065-1073. PubMed ID: 28633324
[TBL] [Abstract][Full Text] [Related]
17. Mammographic patterns as a predictive biomarker of breast cancer risk: effect of tamoxifen.
Atkinson C; Warren R; Bingham SA; Day NE
Cancer Epidemiol Biomarkers Prev; 1999 Oct; 8(10):863-6. PubMed ID: 10548313
[TBL] [Abstract][Full Text] [Related]
18. Quality of Life in a Randomized Breast Cancer Prevention Trial of Low-Dose Tamoxifen and Fenretinide in Premenopausal Women.
Serrano D; Gandini S; Guerrieri-Gonzaga A; Feroce I; Johansson H; Macis D; Aristarco V; Bonanni B; DeCensi A
Cancer Prev Res (Phila); 2018 Dec; 11(12):811-818. PubMed ID: 30352838
[TBL] [Abstract][Full Text] [Related]
19. Use of Low-Dose Tamoxifen to Increase Mammographic Screening Sensitivity in Premenopausal Women.
Eriksson M; Czene K; Conant EF; Hall P
Cancers (Basel); 2021 Jan; 13(2):. PubMed ID: 33467653
[TBL] [Abstract][Full Text] [Related]
20. Influence of hormone replacement therapy on tamoxifen-induced vasomotor symptoms.
Sestak I; Kealy R; Edwards R; Forbes J; Cuzick J
J Clin Oncol; 2006 Aug; 24(24):3991-6. PubMed ID: 16921052
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]